Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech market research

Frost & Sullivan 2026 AI Healthcare Blue Book

Analysis based on 6 articles · First reported Sep 17, 2026 · Last updated Sep 18, 2026

Sentiment
5
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The report is a research publication rather than a transactional event, so direct market impact is limited and largely informational for investors tracking AI healthcare themes. It may modestly support sentiment toward AI healthcare and medical imaging companies by highlighting commercialization progress and regulatory clarity, but no specific company financials or guidance are affected.

healthcare artificial intelligence medical devices

Frost & Sullivan published the 2026 Blue Book on the Development of the Global AI Healthcare Industry, a comprehensive research report analyzing the global AI healthcare landscape. The Blue Book covers the definition and evolution of AI healthcare, core technical frameworks, value chain analysis, and growth drivers. It examines application scenarios including AI-assisted clinical diagnosis, disease treatment, healthcare administration and operations, payment and insurance innovation, and drug lifecycle management. Medical imaging has led commercialization due to standardized data, clear clinical needs, and established regulatory pathways, while applications expand into pathology and laboratory diagnosis. The report compares development across major markets: the United States emphasizes regulatory access, real-world validation, and commercialization; Europe focuses on trustworthy governance, data security, and compatibility with public healthcare systems; and China is advancing from single-point applications toward platform-based deployment. Regulatory frameworks are becoming more systematic, extending beyond product approval toward lifecycle governance including algorithm updates, model performance, data governance, transparency, and post-market monitoring. The Blue Book also introduces companies in the AI healthcare field and analyzes development challenges and future trends, noting competition is shifting from individual algorithm performance toward comprehensive capabilities in data governance, model iteration, clinical validation, system integration, and compliance operations.

90 Frost & Sullivan published blue book
priv
Frost & Sullivan authored and published the 2026 Blue Book, reinforcing its position as a growth-strategy and market research firm covering AI healthcare.
Importance 95.0 Sentiment 10.0
cnt
China is highlighted as advancing from single-point AI healthcare applications toward broader platform-based deployment, positioning it as a key growth market in the report.
Importance 40.0 Sentiment 5.0
cnt
The United States is described as emphasizing regulatory access, real-world validation, and commercialization in AI healthcare, indicating a mature but compliance-focused market.
Importance 35.0 Sentiment 5.0
loc
Europe is characterized as focusing on trustworthy governance, data security, and compatibility with public healthcare systems, shaping its AI healthcare adoption path.
Importance 30.0 Sentiment 5.0
Frost & Sullivan related ↔ China
China strategic rival ↔ United States China views the United States as a strategic rival, actively competing across economic, technological, and military doma
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.